ArrowMark Colorado Holdings Trims Stake in CG Oncology

Institutional investor reduces holdings in clinical-stage biotech company

Mar. 16, 2026 at 7:24am

Got story updates? Submit your updates here. ›

ArrowMark Colorado Holdings LLC, an institutional investor, has reduced its position in CG Oncology, Inc. (NASDAQ:CGON) by 12.2% in the third quarter, according to a recent SEC filing. The firm now owns 257,230 shares of the company's stock, valued at $10.36 million.

Why it matters

CG Oncology is a clinical-stage biotech company focused on developing novel antibody-based immunotherapies for solid tumor cancers. The reduction in ArrowMark's stake could signal a shift in investor sentiment or portfolio rebalancing, which could impact the company's stock price and access to capital.

The details

According to the 13F filing, ArrowMark Colorado Holdings sold 35,776 shares of CG Oncology during the third quarter, reducing its total holdings to 257,230 shares. The firm now owns approximately 0.34% of the company's outstanding shares. Other institutional investors, including Candriam S.C.A. and Vanguard Group Inc., have also made changes to their CG Oncology positions in recent quarters.

  • ArrowMark Colorado Holdings filed its 13F report for the third quarter of 2026.

The players

ArrowMark Colorado Holdings LLC

An institutional investment firm that manages a portfolio of public and private equity investments.

CG Oncology, Inc.

A clinical-stage biopharmaceutical company focused on developing novel antibody-based immunotherapies for solid tumor cancers.

Got photos? Submit your photos here. ›

The takeaway

The reduction in ArrowMark Colorado Holdings' stake in CG Oncology could signal a shift in investor sentiment or portfolio rebalancing, which could impact the company's stock price and access to capital as it continues to develop its pipeline of cancer immunotherapies.